Table 2. Excess absolute risk and excess relative risk by subtype and variables of interest*.
| All leukemia (no CLL) | AML | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| No. | EAR (95% CI) | ERR (95% CI) | No. | EAR (95% CI) | ERR (95%CI) | |
| Total, unadjusted | 89 | 10.8 (7.6–14.6) | 1.6 (1.0–2.2) | 53 | 7.2 (4.7–10.2) | 2.1 (1.3–2.9) |
| Latency† | ||||||
| 1–4yr | 32 | 17.9 (11.2–26.2) | 4.6 (2.9–6.8) | 22 | 12.9 (7.6–20.1) | 8.0 (4.7–12.4) |
| 5–9 yr | 18 | 8.0 (3.0–14.9) | 1.8 (0.6–3.3) | 12 | 6.0 (2.0–11.8) | 3.0 (1.1–6.0) |
| 10–14 yr | 13 | 6.8 (1.1–15.3) | 1.2 0.2–2.8) | 5 | 2.2 (<0–8.0) | 0.8 (<0–3.0) |
| ⩾15 yr | 26 | 8.1 (1.2–17.4) | 0.8 (0.1–1.7) | 14 | 5.1 (0.6–12.0) | 0.9 (0.2–2.2) |
| p Trend | 0.051 | <0.001 | 0.034 | <0.001 | ||
| Age at TC diagnosis‡ | ||||||
| < 30 yr | 27 | 18.6 (9.8–31.7) | 7.7 (41–13.1) | 20 | 16.1 (8.1–38.5) | 17.1 (8.8–30.0) |
| 30–39 yr | 23 | 13.3 (5.8–24.7) | 3.7 (1.6–7.1) | 10 | 5.6 (1.1–13.7) | 4.0 (0.9–9.6) |
| ⩾40 yr | 39 | 23.2 (10.9–40.5) | 2.5 (1.0–4.4) | 23 | 17.8 (7.8–33.2) | 3.7 (1.4–7.2) |
| p Trend | 0.415 | 0.006 | >0.50 | 0.002 | ||
| Attained age‡ | ||||||
| <40yr | 27 | 16.5 (9.5–25.9) | 5.7 (3.3–9.1) | 17 | 11.7 (6.1–19.7) | 10.2 (5.3–17.3) |
| 40–49 yr | 21 | 19.3 (8.7–36.0) | 4.5 (2.0–8.4) | 12 | 13.2 (4.9–27.6) | 6.8 (2.6–14.2) |
| ⩾50yr | 41 | 23.9 (9.3–47.8) | 1.7 (0.6–3.4) | 24 | 20.0 (7.2–42.9) | 2.6 (0.8–5.9) |
| p Trend | >0.50 | <0.001 | >0.50 | <0.001 | ||
| Initial treatment§,∥ | ||||||
| Radiotherapy only | 39 | 19.5 (10.0–33.7) | 5.3 (2.7–9.2) | 20 | 10.5 (3.9–21.3) | 6.3 (2.4–12.8) |
| Any chemotherapy | 10 | 22.5 (8.0–46.7) | 6.1 (2.0–12.8) | 9 | 24.6 (9.5–50.5) | 14.6 (5.5–29.9) |
| p Diff | >0.50 | >0.50 | 0.131 | 0.142 | ||
| Calendar year of TC diagnosis | ||||||
| All treatments§,¶ | ||||||
| <1975 | 30 | 19.8 (8.2–39.1) | 4.0 (1.5–8.4) | 13 | 7.1 (<0–19.9) | 3.3 (<0–10.4) |
| 1975+ | 59 | 17.5 (10.7–26.3) | 4.7 (2.9–7.1) | 40 | 14.2 (8.2–22.3) | 8.7 (5.1–13.6) |
| p Diff | >0.50 | >0.50 | 0.230 | 0.103 | ||
| Radiotherapv only§,∥ | ||||||
| <1975 | 19 | 23.5 (7.4–56.3) | 5.8 (1.8–14.5) | 9 | 8.7 (<0-30.7) | 5.3 (0.5–20.6) |
| 1975+ | 20 | 16.2 (5.9–33.7) | 4.8 (1.8–9.7) | 11 | 7.9 (1.6–21.4) | 5.1 (1.1–13.2) |
| p Diff | 0.491 | >0.50 | >0.50 | >0.50 | ||
CLL = chronic lymphocytic leukemia; AML = acute myeloid leukemia; EAR = excess absolute risk; ERR = excess relative risk; TC = testicular cancer; Diff = difference.
EAR = excess cases per 100,000 person-years, p Values represent likelihood ratio test. As indicated below, estimates adjusted for latency are shown for period 1—4 years since testicular cancer diagnosis and estimates adjusted for age at testicular diagnosis are presented for age 35 years.
Adjusted for age at testicular cancer diagnosis only.
Adjusted for latency only.
Adjusted for latency and age at diagnosis ot testicular cancer.
Includes only those registries that collect data on initial treatment (i.e., SEER Program, Denmark, Finland, Norway).
Reflects all registries, including those registries that do not collect initial treatment data.